Alector, Inc. — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023; this is an annual report, not a standalone fourth-quarter filing. Alector is a clinical-stage biotechnology company with no approved products and no product-sale revenue. Collaboration revenue is its principal reported revenue.
Financial performance and liquidity
| Metric | FY2023 | FY2022 |
|---|---|---|
| Collaboration revenue | $97.1 million | $133.6 million |
| Research and development expense | $192.1 million | $210.4 million |
| General and administrative expense | $56.7 million | $61.0 million |
| Operating loss | $151.7 million | $137.8 million |
| Other income, net | $26.6 million | $7.8 million |
| Net loss | $130.4 million | $133.3 million |
| Net loss per share, basic and diluted | $1.56 | $1.62 |
| Cash used in operating activities | $184.2 million | $20.3 million |
At year-end, cash, cash equivalents, and marketable securities totaled $548.9 million; total assets were $621.8 million, total liabilities $487.7 million, and stockholders’ equity $134.2 million. Deferred revenue was $293.8 million. The filing does not report a borrowing or debt balance in the presented balance sheet. No product-sales margins are available; the company remains loss-making.
In January 2024, Alector received approximately $71.1 million in net proceeds from a public offering. Including those proceeds, management estimated available funding of $620.0 million and expected cash runway through 2026; this is a forward-looking estimate dependent on assumptions about spending and development plans.
Material changes and business developments
- Collaboration revenue fell $36.6 million year over year, primarily reflecting a $68.9 million revenue recognition adjustment in 2022 after termination of the AL003 program and lower latozinemab revenue. Higher AL101 and AL002 revenue partly offset the decline.
- Operating expenses decreased $22.6 million, including lower R&D and G&A costs. R&D spending rose for AL002 to $51.5 million from $34.8 million, while spending on other programs fell to $21.1 million from $44.9 million.
- Despite lower expenses, operating loss increased by $13.9 million as revenue declined. Net loss narrowed by $2.9 million, helped by higher interest income on investments.
- Operating cash use increased substantially from 2022, principally reflecting a $66.8 million decrease in deferred revenue and a $24.5 million decrease in the collaboration-partner refund liability. Investing cash flow was positive $101.9 million, primarily from marketable-security maturities exceeding purchases.
- Alector reduced its workforce by approximately 11%—about 30 employees—in March 2023, incurring approximately $1.7 million in restructuring costs.
Programs, outlook, and key risks
- Latozinemab (FTD-GRN): The pivotal Phase 3 INFRONT-3 trial reached target enrollment in October 2023, with 103 symptomatic and 16 at-risk participants enrolled. The primary analysis is focused on symptomatic participants and treatment is planned for 96 weeks. Enrollment completion remains subject to revised-protocol approval in some countries. In February 2024, the FDA granted Breakthrough Therapy Designation. Earlier open-label Phase 2 findings are not confirmatory evidence of efficacy.
- AL002 (Alzheimer’s disease): Enrollment in the Phase 2 INVOKE-2 trial reached 381 in the third quarter of 2023; data were expected in the fourth quarter of 2024. Treatment-emergent MRI findings resembling ARIA have occurred, including a small number of serious adverse events. Dosing and enrollment of APOE e4/e4 participants were discontinued; MRI monitoring was increased and the trial remains under independent monitoring.
- AL101 (Alzheimer’s disease): GSK dosed the first participant in the global Phase 2 PROGRESS-AD trial in February 2024. Under the 2023 amendment, Alector is responsible for funding and sharing development costs up to $140.5 million for the initial Phase 2 trial. The GSK agreement’s estimated transaction price was reduced following contract modifications and refund-liability estimates.
- GSK collaboration terms include potential additional milestones of up to $1.5 billion; these are contingent, not assured. In the United States, the parties generally share commercialization profits and losses; outside the United States, GSK commercializes and Alector may receive tiered royalties. AbbVie may exercise its AL002 option for $250 million; exercise is not assured. AbbVie terminated the CD33 program, and Alector received $30.3 million in 2023 milestone and enrollment-related payments under the AL002 amendment.
- Management expects continued significant losses and R&D spending and does not expect product revenue in the near term. Funding runway estimates may prove inaccurate; additional capital may be needed. Key risks include clinical failure or delay, AL002 safety findings, reliance on collaborators and contract manufacturers, competitive therapies, regulatory uncertainty, and dilution or unfavorable terms if further financing is required.
Auditors issued unqualified opinions on the financial statements and internal control over financial reporting; management also concluded disclosure controls were effective. The auditor identified collaboration revenue recognition as a critical audit matter because it depends on estimates of total costs to satisfy performance obligations.
Important facts for investors to verify
- Progress, protocol approvals, and timing of results for INFRONT-3 and the expected 2024 INVOKE-2 readout.
- Further information on the frequency, severity, and management of ARIA-like MRI findings in INVOKE-2.
- Actual AL101 trial costs against Alector’s $140.5 million commitment, and changes to GSK collaboration refund-liability estimates.
- Cash burn, investment balances, and whether the projected runway through 2026 remains achievable.
- Any AbbVie option decision for AL002 and the status and conditions of potential collaboration milestones.